These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33975674)

  • 1. Cotrimoxazole for community-acquired urinary tract infections leads to more adverse effects than fluoroquinolones.
    Michelangeli C; Courjon J; Curlier E; Roger PM
    Infect Dis Now; 2021 Jun; 51(4):374-376. PubMed ID: 33975674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefazolin versus fluoroquinolones for the treatment of community-acquired urinary tract infections in hospitalized patients.
    Uppala A; King EA; Patel D
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1533-1538. PubMed ID: 31114972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current prescribing practices and guideline concordance for the treatment of uncomplicated urinary tract infections in women.
    Langner JL; Chiang KF; Stafford RS
    Am J Obstet Gynecol; 2021 Sep; 225(3):272.e1-272.e11. PubMed ID: 33848538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of bone and joint infections caused by Enterobacter cloacae with a fluoroquinolone-cotrimoxazole combination.
    Cisse H; Vernet-Garnier V; Hentzien M; Bajolet O; Lebrun D; Bonnet M; Ohl X; Diallo S; Bani-Sadr F
    Int J Antimicrob Agents; 2019 Aug; 54(2):245-248. PubMed ID: 31096009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source.
    Sutton JD; Stevens VW; Chang NN; Khader K; Timbrook TT; Spivak ES
    JAMA Netw Open; 2020 Oct; 3(10):e2020166. PubMed ID: 33030555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli.
    Rattanaumpawan P; Nachamkin I; Bilker WB; Roy JA; Metlay JP; Zaoutis TE; Lautenbach E;
    Ann Clin Microbiol Antimicrob; 2017 Apr; 16(1):25. PubMed ID: 28390438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolones for urinary tract infection and within-household spread of resistant Enterobacteriaceae: the smoking gun.
    Trautner BW
    Clin Microbiol Infect; 2018 Sep; 24(9):929-930. PubMed ID: 29649605
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibiotic prescribing patterns for adult urinary tract infections within emergency department and urgent care settings.
    Maddali N; Cantin A; Koshy S; Eiting E; Fedorenko M
    Am J Emerg Med; 2021 Jul; 45():464-471. PubMed ID: 33067064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of CTX-M-15 beta-lactamases in Enterobacteriaceae causing hospital- and community-acquired urinary tract infections as early as 2004, in Dar es Salaam, Tanzania.
    Manyahi J; Moyo SJ; Tellevik MG; Ndugulile F; Urassa W; Blomberg B; Langeland N
    BMC Infect Dis; 2017 Apr; 17(1):282. PubMed ID: 28415986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.
    Tseng YT; Chuang YC; Shu CC; Hung CC; Hsu CF; Wang JY
    Crit Care; 2012 Oct; 16(5):R207. PubMed ID: 23098258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.
    Pradelli J; Risso K; de Salvador FG; Cua E; Ruimy R; Roger PM
    Eur J Clin Microbiol Infect Dis; 2015 Mar; 34(3):511-8. PubMed ID: 25273975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections.
    Cowart K; Worley M; Rouby NE; Sando K
    Ann Pharmacother; 2019 Dec; 53(12):1192-1199. PubMed ID: 31319681
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of Fluoroquinolones or Sulfamethoxazole-Trimethoprim Compared to Β-Lactams for Oral Step-Down Therapy in Hospitalized Patients With Uncomplicated Enterobacterales Bacteremia.
    Mack T; Hiles JJ; Wrin J; Desai A
    Ann Pharmacother; 2023 Mar; 57(3):251-258. PubMed ID: 35758168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
    de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
    Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous-only or Intravenous Transitioned to Oral Antimicrobials for Enterobacteriaceae-Associated Bacteremic Urinary Tract Infection.
    Rieger KL; Bosso JA; MacVane SH; Temple Z; Wahlquist A; Bohm N
    Pharmacotherapy; 2017 Nov; 37(11):1479-1483. PubMed ID: 28869655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of disability in patients exposed to fluoroquinolones.
    Wilcox MA; Villasis-Keever A; Sena AG; Knoll C; Fife D
    BMC Pharmacol Toxicol; 2020 Jun; 21(1):40. PubMed ID: 32493505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Urinary Tract Infections Caused by Community-Acquired Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in a Level III Hospital - A Retrospective Study].
    Simões A; Lima M; Brett A; Queiroz C; Chaves C; Oliveira H; Januário L; Rodrigues F
    Acta Med Port; 2020 Jul; 33(7-8):466-474. PubMed ID: 31962058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
    Pang F; Jia XQ; Zhao QG; Zhang Y
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study.
    Zilberberg MD; Nathanson BH; Sulham K; Shorr AF
    BMC Infect Dis; 2021 Feb; 21(1):159. PubMed ID: 33557769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.